Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
Completed
Conditions studied: Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
In brief
Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment. Purpose: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with locally advanced or metastatic kidney cancer.
Key facts
- Study ID
- NCT01026337
- Run by
- Abramson Cancer Center at Penn Medicine
- People needed
- 43
- Starts
- 2009-04-01
- Expected to finish
- 2018-11-01
- Last updated by the study team
- 2019-06-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Abramson Cancer Center of The University of Pennsylvania — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.